News
9h
Stocktwits on MSNUroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s UnruffledShares of biotech company UroGen Pharma Ltd. (URGN) plummeted 48% on Wednesday noon after the company said that a committee ...
Satsuma, a unit of a Japanese drugmaker with U.S. headquarters in Durham, said its treatment, called Atzumi, received its new ...
Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...
Pfizer also plans to make a $100 million equity investment in the Chinese biotechnolgoy company after the transaction closes, ...
The initiatives reflect the latest measures from federal agencies to reduce and ultimately replace animal testing in drug development and ...
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug ...
The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.
The FDA has cleared investigational new drug applications and handed out fast track designations. Plus, data shows promise for novel therapies in hard-to-treat cancers.
8d
Pharmaceutical Technology on MSNFDA clears Ensoma’s application for rare genetic disorder treatmentThe FDA has cleared the IND for Ensoma's EN-374, targeting X-linked chronic granulomatous disease (X-CGD), a rare genetic ...
The partnership with top health agencies and companies like Mark Cuban's Cost Plus Drug Company aims to use AI to produce ...
A new once-daily pill may raise the bar for weight loss meds. Ozempic, Mounjaro and similar drugs that mimic the GLP-1 hormone the body naturally produces after eating can cause significant weight ...
Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results